阿德福韦酯联合胸腺肽α1治疗慢性乙型肝炎疗效分析  

Curative Effect Analysis of Chronic Hepatitis B Treated by Adefovir Dipivoxil Combined withThymosin α1

作　　者：蒋阳昆[1] 陈黎[1] 张红星[1] 林海[1] 

机构地区：[1]广西中医学院附属瑞康医院,南宁530011

出　　处：《实用中西医结合临床》2010年第5期9-10,共2页Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:观察阿德福韦酯联合胸腺肽α1治疗慢性乙型肝炎(CHB)的疗效。方法:将86例HBeAg阳性的CHB患者随机分为联合治疗组和对照组各43例,联合治疗组同时使用阿德福韦酯与胸腺肽α124周,随后单用阿德福韦酯28周;对照组单用阿德福韦酯52周。观察两组患者治疗24周及52周时的HBeAg/HBeAb血清转换率、血清HBeAg转阴率、HBV-DNA转阴率及肝功能复常率。结果:治疗52周时联合治疗组HBeAg/HBeAb血清转换率、血清HBeAg转阴率、HBV-DNA转阴率及肝功能复常率明显高于对照组,两组比较有显著差异(P<0.05)。结论:阿德福韦酯联合胸腺肽α1治疗CHB的确具有协同抗HBV效应。Objective：To observe the effect of adefovirand thymosin α1 treatment of chronic hepatitis B（CHB）.Methods：86 Patients with HBeAg-positive CHB were randomly divided into combined treatment group and control group,combined treatment group using both adefovirand thymosin α1 24 weeks,followed by 28 weeks of adefovirdipivoxil alone;control group only 52 weeks with adefovirdipivoxil.2 groups were observed for 24 weeks and 52 weeks of HBeAg/HBeAb seroconversion rate,serum HBeAg negative rate,HBV-DNA negative rate and liver function recovery rate.Results：The combined treatment group after 52 weeks,HBeAg/HBeAb seroconversion rate,serum HBeAg negative rate,HBV-DNA negative rate and liverfunction recovery rate were significantly higherthan contrel group,the two groups were significantly different（P〈0.05）.Conclusion：The treatment of adefovir combined with thymosin α1 does have a synergistic anti-HBV effect.

关 键 词：慢性乙型肝炎 阿德福韦酯 胸腺肽Α1 

分 类 号：R512.62[医药卫生—内科学]